Cardiac manifestations in antiphospholipid syndrome - a brief review of the literature
Antiphospholipid syndrome (APS) or Hughes syndrome represents a systemic autoimmune disorder characterized by arterial and/or venous thrombosis, multiple and recurrent fetal losses, accompanied by persistently elevated levels of antiphospholipid antibodies (aPL). This syndrome is considered...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Serbian Medical Society
2015-01-01
|
Series: | Srpski Arhiv za Celokupno Lekarstvo |
Subjects: | |
Online Access: | http://www.doiserbia.nb.rs/img/doi/0370-8179/2015/0370-81791506346D.pdf |
id |
doaj-86feee5d086847168316fa067f5d6621 |
---|---|
record_format |
Article |
spelling |
doaj-86feee5d086847168316fa067f5d66212021-01-02T09:29:54ZengSerbian Medical SocietySrpski Arhiv za Celokupno Lekarstvo0370-81792015-01-011435-634635310.2298/SARH1506346D0370-81791506346DCardiac manifestations in antiphospholipid syndrome - a brief review of the literatureĐoković Aleksandra0Stojanović Ljudmila1Clinical Hospital Center “Bežanijska kosa”, Clinic for Internal Medicine, BelgradeClinical Hospital Center “Bežanijska kosa”, Clinic for Internal Medicine, BelgradeAntiphospholipid syndrome (APS) or Hughes syndrome represents a systemic autoimmune disorder characterized by arterial and/or venous thrombosis, multiple and recurrent fetal losses, accompanied by persistently elevated levels of antiphospholipid antibodies (aPL). This syndrome is considered primary if unassociated with any other connective tissue disease, or secondary if it appears in association with other autoimmune disorders, mainly systemic lupus erythematosus. Cardiac manifestations in APS are integral part of the syndrome. aPL are involved in the pathogenesis of pseudoinfective endocarditis (Libman Sacks) and other valvular manifestations presented as their thickening and dysfunction. Intracardiac thrombi and myxomas, pulmonary hypertension and left ventricular dysfunction are also distinguishing features of APS. On the other hand, accelerated atherosclerosis, proven in APS and also aPL mediated, is accountable for the development of coronary and peripheral artery disease. This leads to higher cardiovascular mortality rate in the population of patients with low incidence of the traditional atherosclerosis risk factors. Furthermore, recent studies implied that presence of certain aPL could be a risk factor for a specific cardiac manifestation. Bearing all this in mind, early diagnosis of cardiac manifestations, control and abolition of traditional risk factors, as well as close cardiac follow-up of APS patients, are crucial in reducing their cardiovascular mortality.http://www.doiserbia.nb.rs/img/doi/0370-8179/2015/0370-81791506346D.pdfcardiac manifestationsantiphospholipid syndromeantiphospholipid antibodiesmultidisciplinary approach |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Đoković Aleksandra Stojanović Ljudmila |
spellingShingle |
Đoković Aleksandra Stojanović Ljudmila Cardiac manifestations in antiphospholipid syndrome - a brief review of the literature Srpski Arhiv za Celokupno Lekarstvo cardiac manifestations antiphospholipid syndrome antiphospholipid antibodies multidisciplinary approach |
author_facet |
Đoković Aleksandra Stojanović Ljudmila |
author_sort |
Đoković Aleksandra |
title |
Cardiac manifestations in antiphospholipid syndrome - a brief review of the literature |
title_short |
Cardiac manifestations in antiphospholipid syndrome - a brief review of the literature |
title_full |
Cardiac manifestations in antiphospholipid syndrome - a brief review of the literature |
title_fullStr |
Cardiac manifestations in antiphospholipid syndrome - a brief review of the literature |
title_full_unstemmed |
Cardiac manifestations in antiphospholipid syndrome - a brief review of the literature |
title_sort |
cardiac manifestations in antiphospholipid syndrome - a brief review of the literature |
publisher |
Serbian Medical Society |
series |
Srpski Arhiv za Celokupno Lekarstvo |
issn |
0370-8179 |
publishDate |
2015-01-01 |
description |
Antiphospholipid syndrome (APS) or Hughes syndrome represents a systemic
autoimmune disorder characterized by arterial and/or venous thrombosis,
multiple and recurrent fetal losses, accompanied by persistently elevated
levels of antiphospholipid antibodies (aPL). This syndrome is considered
primary if unassociated with any other connective tissue disease, or
secondary if it appears in association with other autoimmune disorders,
mainly systemic lupus erythematosus. Cardiac manifestations in APS are
integral part of the syndrome. aPL are involved in the pathogenesis of
pseudoinfective endocarditis (Libman Sacks) and other valvular manifestations
presented as their thickening and dysfunction. Intracardiac thrombi and
myxomas, pulmonary hypertension and left ventricular dysfunction are also
distinguishing features of APS. On the other hand, accelerated
atherosclerosis, proven in APS and also aPL mediated, is accountable for the
development of coronary and peripheral artery disease. This leads to higher
cardiovascular mortality rate in the population of patients with low
incidence of the traditional atherosclerosis risk factors. Furthermore,
recent studies implied that presence of certain aPL could be a risk factor
for a specific cardiac manifestation. Bearing all this in mind, early
diagnosis of cardiac manifestations, control and abolition of traditional
risk factors, as well as close cardiac follow-up of APS patients, are crucial
in reducing their cardiovascular mortality. |
topic |
cardiac manifestations antiphospholipid syndrome antiphospholipid antibodies multidisciplinary approach |
url |
http://www.doiserbia.nb.rs/img/doi/0370-8179/2015/0370-81791506346D.pdf |
work_keys_str_mv |
AT đokovicaleksandra cardiacmanifestationsinantiphospholipidsyndromeabriefreviewoftheliterature AT stojanovicljudmila cardiacmanifestationsinantiphospholipidsyndromeabriefreviewoftheliterature |
_version_ |
1724356048640278528 |